Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:52:13.287Z.
Calculation as of: 2026-10-06T21:52:13.287Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4147f1633fe526555426f89ecb5945f37dfc8ef4561f7e6db8f1148c00751c21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$5.79B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.87B
EV/EBITDA Ratio
55.94x
TTM Avg
88.38x
3Y Avg
133.43x
5Y Avg
103.02x
Market Cap
$5.95B
EV/EBITDA Ratio
45.02x
TTM Avg
617.82x
3Y Avg
545.60x
5Y Avg
321.06x
Market Cap
$5.52B
EV/EBITDA Ratio
30.67x
TTM Avg
33.01x
3Y Avg
33.01x
5Y Avg
33.01x
Market Cap
$6.23B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 55.94x | 88.38x | 133.43x | 103.02x |
| GRAIL Inc. (GRAL)vs › | $5.89B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 45.02x | 617.82x | 545.60x | 321.06x |
| RadNet, Inc. (RDNT)vs › | $5.53B | 21.70x | 24.95x | 22.12x | 17.84x |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 30.67x | 33.01x | 33.01x | 33.01x |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 28.93x | 14.09x | 107.60x | 107.60x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
